Skip to main content

HIPRA’s COVID-19 vaccine trial in people with immunocompromising conditions was launched in Turkey


It has started in Turkey the clinical trial for HIPRA’s COVID-19 vaccine in people with immunocompromising conditions. This trial will determine if an additional dose of HIPRA’s COVID-19 vaccine can generate an immune response in immunocompromised people.

60 adults volunteers will participate in this clinical trial from two hospitals in Ankara and one in Istanbul.

This trial, led by HIPRA, is carried out in the framework of the European-funded RBDCOV project.

Press material